Affiliation: National Institute for Medical Research
- Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in childrenH Green
MRC Clinical Trials Unit, 222 Euston Road, London, NW1 2DA, UK
AIDS 21:947-55. 2007..To describe the long-term efficacy over 5 years of regimens including combinations of abacavir, lamivudine and/or zidovudine in previously untreated children in the PENTA 5 trial...
- First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trialAbdel Babiker
MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
Lancet Infect Dis 11:273-83. 2011..We assess the long-term outcome of protease inhibitor and non-nucleoside reverse transcriptase inhibitor (NNRTI) first-line ART and viral load switch criteria in children...
- Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcomeJ-P Aboulker
AIDS 18:237-45. 2004..However, a high rate of virological failure with emergence of genotypic resistance is of great concern. More palatable drug combinations for infants and closer drug monitoring are required...
- Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected childrenTim R Cressey
Institut de Recherche pour le Developpement, Program for HIV Prevention and Treatment, UR 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
Clin Infect Dis 46:1601-8. 2008....